Table 2.
Outcome | HR (95% CI) | P |
---|---|---|
Grade 2-4 acute GVHD | ||
HLA-matched unrelated | 1.00 | |
HLA-haploidentical relative | 0.44 (0.31-0.62) | <.0001 |
Grade 3-4 acute GVHD | ||
HLA-matched unrelated | 1.00 | |
HLA-haploidentical relative | 0.26 (0.14-0.48) | <.0001 |
Chronic GVHD | ||
HLA-matched unrelated | 1.00 | |
HLA-haploidentical relative | 0.36 (0.25-0.53) | <.0001 |
NRM* | ||
HLA-matched unrelated | 1.00 | |
HLA-haploidentical relative | 0.90 (0.62-1.31) | .57 |
Relapse† | ||
HLA-matched unrelated | 1.00 | |
HLA-haploidentical relative | 1.56 (1.14-2.14) | .0055 |
DFS‡ | ||
HLA-matched unrelated | 1.00 | |
HLA-haploidentical relative | 1.29 (1.01-1.65) | .042 |
OS§ | ||
HLA-matched unrelated | 1.00 | |
HLA-haploidentical relative | 0.94 (0.71-1.24) | .65 |
Each patient was assigned a propensity score based on age, KPS, HMAs before transplantation and IPSS-R score at transplantation.
HR, hazard ratio.
Adjusted for recipient CMV serostatus.
Adjusted for recipient sex.
Adjusted for donor-recipient sex match.
Adjusted for HCT-CI score.